<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.114242</article-id><article-id pub-id-type="publisher-id">ACM-41715</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210400000_88169544.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  CHADS2与CHA2DS2-VASc评分预测房颤卒中患者颅内外大动脉粥样硬化狭窄
  Predicting Large Atherosclerotic Stenosis with CHADS2 and CHA2DS2-VASc Scores in Stroke Patients with Atrial Fibrillation
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吴</surname><given-names>昊</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>魏</surname><given-names>淑琦</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>赵</surname><given-names>仁亮</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>04</month><year>2021</year></pub-date><volume>11</volume><issue>04</issue><fpage>1686</fpage><lpage>1694</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨CHADS2与CHA2DS2-VASc评分及评分项目预测非瓣膜性房颤并发急性缺血性卒中患者(房颤卒中)合并颅内外大动脉粥样硬化狭窄的可能性。方法：选择2018年1月至2020年1月住院治疗的非瓣膜性房颤合并急性缺血性卒中患者，根据是否存在颅内外大动脉粥样硬化狭窄标准分组，按照CHADS2评分与CHA2DS2-VASc评分项目统计患者入院时基线资料及相关实验室检查结果，对入组患者行CHADS2评分及CHA2DS2-VASc评分，并通过影像学评估颅脑结构及颅内外血管病变。结果：共入组202例房颤卒中患者，其中，合并颅内外大动脉粥样硬化狭窄病例137例(67.8%)。与未合并大动脉粥样硬化狭窄组相比，合并大动脉粥样硬化狭窄组年龄、血管疾病比例及CHA2DS2-VASc评分较高，心力衰竭比例较低。经Logistic回归分析，年龄与心力衰竭与是否合并大动脉粥样硬化狭窄独立相关。绘制ROC曲线，AUC值表明CHADS2评分项目[AUC = 0.705 (0.628~0.782), P &lt; 0.001]、CHA2DS2-VASc评分[AUC = 0.724 (0.650~0.797), P &lt; 0.05]及评分项目[AUC = 0.731 (0.655~0.806), P &lt; 0.001]可预测房颤卒中合并颅内外大动脉粥样硬化狭窄。结论：在房颤合并卒中患者中，CHA2DS2-VASc评分及评分项目预测房颤卒中合并颅内外大动脉粥样硬化狭窄的效能更佳。
    Objective: To explore the possibility of CHADS2 and CHA2DS2-VASc scores and scoring items in predicting the possibility of non-valvular atrial fibrillation (NVAF) complicated by acute ischemic stroke (AIS) with intra/extracranial large atherosclerotic stenosis (LAS). Methods: AIS patients with NVAF who were hospitalized from January 2018 to January 2020 were enrolled, and were grouped according to the standard of intra/extracranial atherosclerosis stenosis. The baseline datas and relevant laboratory examinations were gathered. CHADS2 scores and CHA2DS2-VASc scores at admission were counted. Imaging evaluation of brain structure and intra/extracranial vascular were practiced. Results: Among the 202 AIS patients with NVAF, 137 cases (67.8%) concomitanted intra/extracranial atherosclerotic stenosis. Compared with the group of patients with intra/extracranial atherosclerotic stenosis (Group A), the age, the proportion of vascular disease and CHA2DS2-VASc score were higher in the group of patients without intra/extracranial atherosclerotic stenosis (Group B), whereas the proportion of heart failure (HF) was lower. Logistic regression analysis showed that the the age and the proportion of HF were independently related to the presence or absence of atherosclerotic stenosis. Receiver operating characteristic (ROC) curve analysis showed that CHADS2 scoring items [area under the curve (AUC) = 0.705 (0.628~0.782), P &lt; 0.001], CHA2DS2-VASc scores [AUC = 0.705 (0.628~0.782), P &lt; 0.001] and scoring items [AUC = 0.731 (0.655~0.806), P &lt; 0.001] can predict atrial fibrillation stroke with intracranial and extracranial atherosclerotic stenosis. Conclusion: In AIS patients with NVAF, The CHA2DS2-VASc score and scoring items are more effective in predicting atrial fibrillation stroke combined with intra/extracranial atherosclerotic stenosis. 
  
 
</p></abstract><kwd-group><kwd>心房颤动，脑卒中，动脉粥样硬化，CHA2DS2-VASc评分, Atrial Fibrillation</kwd><kwd> Stroke</kwd><kwd> Arteriosclerosis</kwd><kwd> CHA2DS2-VASc Score</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨CHADS2与CHA2DS2-VASc评分及评分项目预测非瓣膜性房颤并发急性缺血性卒中患者(房颤卒中)合并颅内外大动脉粥样硬化狭窄的可能性。方法：选择2018年1月至2020年1月住院治疗的非瓣膜性房颤合并急性缺血性卒中患者，根据是否存在颅内外大动脉粥样硬化狭窄标准分组，按照CHADS2评分与CHA2DS2-VASc评分项目统计患者入院时基线资料及相关实验室检查结果，对入组患者行CHADS2评分及CHA2DS2-VASc评分，并通过影像学评估颅脑结构及颅内外血管病变。结果：共入组202例房颤卒中患者，其中，合并颅内外大动脉粥样硬化狭窄病例137例(67.8%)。与未合并大动脉粥样硬化狭窄组相比，合并大动脉粥样硬化狭窄组年龄、血管疾病比例及CHA2DS2-VASc评分较高，心力衰竭比例较低。经Logistic回归分析，年龄与心力衰竭与是否合并大动脉粥样硬化狭窄独立相关。绘制ROC曲线，AUC值表明CHADS2评分项目[AUC = 0.705 (0.628~0.782), P &lt; 0.001]、CHA2DS2-VASc评分[AUC = 0.724 (0.650~0.797), P &lt; 0.05]及评分项目[AUC = 0.731 (0.655~0.806), P &lt; 0.001]可预测房颤卒中合并颅内外大动脉粥样硬化狭窄。结论：在房颤合并卒中患者中，CHA2DS2-VASc评分及评分项目预测房颤卒中合并颅内外大动脉粥样硬化狭窄的效能更佳。</p></sec><sec id="s2"><title>关键词</title><p>心房颤动，脑卒中，动脉粥样硬化，CHA2DS2-VASc评分</p></sec><sec id="s3"><title>Predicting Large Atherosclerotic Stenosis with CHADS2 and CHA2DS2-VASc Scores in Stroke Patients with Atrial Fibrillation</title><p>Hao Wu, Shuqi Wei, Renliang Zhao<sup>*</sup></p><p>The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/35-1572138x5_hanspub.png" /></p><p>Received: Mar. 15<sup>th</sup>, 2021; accepted: Apr. 13<sup>th</sup>, 2021; published: Apr. 21<sup>st</sup>, 2021</p><p><img src="//html.hanspub.org/file/35-1572138x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To explore the possibility of CHADS2 and CHA2DS2-VASc scores and scoring items in predicting the possibility of non-valvular atrial fibrillation (NVAF) complicated by acute ischemic stroke (AIS) with intra/extracranial large atherosclerotic stenosis (LAS). Methods: AIS patients with NVAF who were hospitalized from January 2018 to January 2020 were enrolled, and were grouped according to the standard of intra/extracranial atherosclerosis stenosis. The baseline datas and relevant laboratory examinations were gathered. CHADS2 scores and CHA2DS2-VASc scores at admission were counted. Imaging evaluation of brain structure and intra/extracranial vascular were practiced. Results: Among the 202 AIS patients with NVAF, 137 cases (67.8%) concomitanted intra/extracranial atherosclerotic stenosis. Compared with the group of patients with intra/extracranial atherosclerotic stenosis (Group A), the age, the proportion of vascular disease and CHA2DS2-VASc score were higher in the group of patients without intra/extracranial atherosclerotic stenosis (Group B), whereas the proportion of heart failure (HF) was lower. Logistic regression analysis showed that the the age and the proportion of HF were independently related to the presence or absence of atherosclerotic stenosis. Receiver operating characteristic (ROC) curve analysis showed that CHADS2 scoring items [area under the curve (AUC) = 0.705 (0.628~0.782), P &lt; 0.001], CHA2DS2-VASc scores [AUC = 0.705 (0.628~0.782), P &lt; 0.001] and scoring items [AUC = 0.731 (0.655~0.806), P &lt; 0.001] can predict atrial fibrillation stroke with intracranial and extracranial atherosclerotic stenosis. Conclusion: In AIS patients with NVAF, The CHA2DS2-VASc score and scoring items are more effective in predicting atrial fibrillation stroke combined with intra/extracranial atherosclerotic stenosis.</p><p>Keywords:Atrial Fibrillation, Stroke, Arteriosclerosis, CHA2DS2-VASc Score</p><disp-formula id="hanspub.41715-formula27"><graphic xlink:href="//html.hanspub.org/file/35-1572138x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/35-1572138x8_hanspub.png" /> <img src="//html.hanspub.org/file/35-1572138x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>心房颤动(Atrial Fibrillation, AF)是心源性卒中的最主要病因。房颤患者罹患缺血性卒中的风险约是无房颤人群的5倍 [<xref ref-type="bibr" rid="hanspub.41715-ref1">1</xref>]。在临床中，经典TOAST分型将房颤与大动脉粥样硬化分为相互独立的卒中病因 [<xref ref-type="bibr" rid="hanspub.41715-ref2">2</xref>]。但既往研究发现，非瓣膜性房颤(Non-valvular atrial fibrillation, NVAF)合并急性缺血性卒中(Acute Ischemic Stroke, AIS)的患者，也常常被证实并发程度不一的颅内或颅外大动脉粥样硬化狭窄(Large atherosclerotic stenosis, LAS) [<xref ref-type="bibr" rid="hanspub.41715-ref3">3</xref>]。针对可能导致房颤患者AIS的二级预防，抗栓方案的制定需更加合理。CHADS2评分与CHA2DS2-VASc评分常被用于评估房颤卒中患者再发卒中风险 [<xref ref-type="bibr" rid="hanspub.41715-ref4">4</xref>]，值得注意的是，左心室节段运动异常和4周内的心肌梗死与CHADS2和CHA2DS2VASC评分较高相关 [<xref ref-type="bibr" rid="hanspub.41715-ref5">5</xref>]，而这类现象也与动脉粥样硬化密切相关，提示在AIS患者中，CHADS2评分与CHA2DS2-VASc评分及其二者的评分项目也可能用于预测颅内外大动脉粥样硬化狭窄。本研究旨在探讨CHADS2与CHA2DS2-VASc评分及评分项目预测非瓣膜性房颤并发急性缺血性卒中患者(房颤卒中)合并颅内外大动脉粥样硬化狭窄的可能性，为精确区分病因分型提供依据。</p></sec><sec id="s6"><title>2. 对象和方法</title><sec id="s6_1"><title>2.1. 研究对象及分组</title><p>纳入2018年1月至2020年1月在我院住院治疗的202例房颤卒中患者。本研究入选患者资料获得受试者的知情同意，并在我院伦理委员会备案。</p><p>纳入标准：1) 符合《中国急性缺血性脑卒中诊治指南2018》诊断标准 [<xref ref-type="bibr" rid="hanspub.41715-ref6">6</xref>]，由颅脑MRI证实；2) 首次发病，发病72 h入院；3) 通过十二导联心电图、动态心电监测或心脏超声等检查确诊合并非瓣膜病颤；4) 临床资料完整；5) 患者知情同意。</p><p>排除标准：1) 曾有脑出血、硬膜下血肿、蛛网膜下腔出血等中枢神经系统疾病等病史；2) 无房颤，或无明确临床证据提示存在房颤；3) 通过十二导联心电图、动态心电监测或心脏超声等检查确诊合并瓣膜病性房颤，或房颤类型不明确；4) 合并动脉夹层、血管炎等可能导致急性缺血性卒中的其他疾病；5) 伴有严重肝、肾功能不全；6) 接受静脉溶栓或血管内治疗的患者；7) 伴有其他重要脏器功能障碍；8) 临床资料不完整。</p></sec><sec id="s6_2"><title>2.2. 基线资料收集</title><p>收集患者的人口学资料，如性别、年龄等；既往史：如高血压、糖尿病、心力衰竭等；高血压诊断标准：满足以下任意一条：1) 未服用降压药情况下，3次非同日测量，收缩压 &#179; 140 mmHg和(或)舒张压 &#179; 90 mmHg；2) 既往诊断高血压，正在服用降压药物的患者 [<xref ref-type="bibr" rid="hanspub.41715-ref7">7</xref>]。糖尿病的诊断标准：满足以下任意一条：1) 典型的糖尿病症状(多饮、多尿、多食、体重下降)并随机血糖 &#179; 11.1 mmol/L；2) 空腹血糖 &#179; 7.0 mmol/L；3) 葡萄糖负荷后2小时血糖 &#179; 11.1 mmol/L (无糖尿病症状者，需改日重复检查)；4) 入院前已明确诊断糖尿病并正在应用降糖药物 [<xref ref-type="bibr" rid="hanspub.41715-ref8">8</xref>]。心力衰竭诊断标准：满足以下标准中(1)及(2)或满足(1)、(3)-(5)或满足(6)：1) 典型心力衰竭的症状和/或体征(呼吸困难、疲乏、液体潴留)；2) 左室射血分数(Left ventricular ejection fraction, LEVF) &lt; 40%；3) N末端B型利钠肽原(N-terminal pro-B-type natriuretic peptide, NTpro-BNP) &gt; 35 ng/L和/或NTpro-BNP &gt; 125 pg/L；4) 左室肥厚和/或左房扩大；5) 心脏舒张功能异常；6) 入院前已明确诊断心力衰竭且正在服用相关药物 [<xref ref-type="bibr" rid="hanspub.41715-ref9">9</xref>]。</p></sec><sec id="s6_3"><title>2.3. 脑结构与脑血管影像学评估</title><p>全部入组患者均完善3.0 T的颅脑核磁共振成像(Magnetic resonance imaging, MRI)、磁共振血管成像(Magnetic Resonance Angiography, MRA)检查、头颈部CT血管成像(CT angiography, CTA)检查及颈部血管超声。</p><p>血管狭窄评估：应用WASID研究所公布的方法 [<xref ref-type="bibr" rid="hanspub.41715-ref10">10</xref>] 计算颅内血管病变狭窄率：狭窄率(%) = (1 − 狭窄最重处血管直径/狭窄近端正常血管直径) &#180; 100%；应用NASCET法计算颅外血管病变狭窄率 [<xref ref-type="bibr" rid="hanspub.41715-ref11">11</xref>]：狭窄率(%) = (1 − 狭窄最重处血管直径/狭窄远端正常血管直径) &#180; 100%。颅内外大动脉狭窄定义为颅内或颅外大动脉狭窄率 ≥ 50%的患者。</p></sec><sec id="s6_4"><title>2.4. 神经功能缺损严重程度及卒中复发风险的评分方法</title><p>应用CHADS2评分与CHA2DS2-VASc评分评估房颤卒中复发风险：CHADS2评分与CHA2DS2-VASc评分通常被用于评估非瓣膜性房颤卒中发生风险，以区分非低危人群并指导抗凝治疗，CHADS2评分与CHA2DS2-VASc评分为0分时不推荐进行抗凝治疗 [<xref ref-type="bibr" rid="hanspub.41715-ref12">12</xref>]。</p></sec><sec id="s6_5"><title>2.5. 血压及血糖指标</title><p>收集入院时血压及空腹血糖指标。</p></sec><sec id="s6_6"><title>2.6. 统计学分析</title><p>应用SPSS 23.0软件行统计学分析。计量资料用均数&#177;标准差( x &#175; &#177; s )或中位数(四分位间距)表示，符合正态分布的组间比较用t检验，否则用非参数检验(Mann-Whitney U检验)。计数资料用频数和百分率(%)表示，两组间比较应用c<sup>2</sup>检验。多因素分析应用logistic回归分析。分析两类连续变量或有序分类变量间关系应用Spearman相关分析。绘制接收者操作特征(receiver operating characteristic, ROC)曲线，用曲线下面积(area under the curve, AUC)分析比较CHADS2评分和CHA2DS2-VASc评分及其组成部分预测房颤卒中患者合并颅内外LAS的能力。P &lt; 0.05为有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 房颤卒中合并/未合并颅内外大动脉粥样硬化狭窄两组患者基线资料分析</title><p>本研究共入组房颤卒中病例202例，其中，合并颅内外大动脉粥样硬化狭窄病例137例(67.8%)，未合并颅内外大动脉粥样硬化狭窄病例65 (32.2%)例。与未合并大动脉粥样硬化狭窄组相比，合并大动脉粥样硬化狭窄组年龄、血管疾病比例较高，心力衰竭比例较低，差异有统计学意义(P &lt; 0.05) (见表1)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Baseline characteristics of patients in Group A and Group B (univariate analysis</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >变量</th><th align="center" valign="middle" >未合并颅内外大动脉粥样硬化狭窄(Group A)</th><th align="center" valign="middle" >合并颅内外大动脉粥样硬化狭窄(Group B)</th><th align="center" valign="middle" >t值、Z值或c<sup>2</sup></th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >人口统计学资料</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >年龄(岁， x &#175; &#177; s )</td><td align="center" valign="middle" >66.65 &#177; 10.15</td><td align="center" valign="middle" >71.96 &#177; 7.73</td><td align="center" valign="middle" >−4.113</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >年龄≥75岁(n，%)</td><td align="center" valign="middle" >15 (23.1%)</td><td align="center" valign="middle" >64 (46.7%)</td><td align="center" valign="middle" >10.344</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >男性(n，%)</td><td align="center" valign="middle" >37 (56.9%)</td><td align="center" valign="middle" >85 (62.0%)</td><td align="center" valign="middle" >0.483</td><td align="center" valign="middle" >0.487</td></tr><tr><td align="center" valign="middle" >既往史(n，%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >心力衰竭</td><td align="center" valign="middle" >39 (60.0%)</td><td align="center" valign="middle" >55 (40.1%)</td><td align="center" valign="middle" >6.984</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >高血压</td><td align="center" valign="middle" >42 (64.6%)</td><td align="center" valign="middle" >87 (40.163.5%)</td><td align="center" valign="middle" >0.024</td><td align="center" valign="middle" >0.561</td></tr><tr><td align="center" valign="middle" >糖尿病</td><td align="center" valign="middle" >28 (43.1%)</td><td align="center" valign="middle" >65(474%)</td><td align="center" valign="middle" >0.339</td><td align="center" valign="middle" >0.617</td></tr><tr><td align="center" valign="middle" >血管疾病</td><td align="center" valign="middle" >7 (10.8%)</td><td align="center" valign="middle" >38 (27.7%)</td><td align="center" valign="middle" >7.331</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >实验室检查</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >收缩压(mmHg， x &#175; &#177; s )</td><td align="center" valign="middle" >151.65 &#177; 24.13</td><td align="center" valign="middle" >148.85 &#177; 23.47</td><td align="center" valign="middle" >0.982</td><td align="center" valign="middle" >0.438</td></tr><tr><td align="center" valign="middle" >舒张压(mmHg， x &#175; &#177; s )</td><td align="center" valign="middle" >85.17 &#177; 12.51</td><td align="center" valign="middle" >82.21 &#177; 11.88</td><td align="center" valign="middle" >1.076</td><td align="center" valign="middle" >0.283</td></tr><tr><td align="center" valign="middle" >空腹血糖(mmol/L， x &#175; &#177; s )</td><td align="center" valign="middle" >6.08 &#177; 1.00</td><td align="center" valign="middle" >6.02 &#177; 1.14</td><td align="center" valign="middle" >0.324</td><td align="center" valign="middle" >0.746</td></tr></tbody></table></table-wrap><p>表1. 房颤卒中合并/未合并颅内外大动脉粥样硬化狭窄两组患者基线资料比较</p></sec><sec id="s7_2"><title>3.2. 多因素logistic回归分析</title><p>将表1中P &lt; 0.1的变量作为自变量，合并颅内外大动脉粥样硬化狭窄为因变量，进行多因素logistic回归分析。分析显示，年龄和心力衰竭比例与是否合并大动脉粥样硬化狭窄独立相关(见表2，P &lt; 0.05)。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Baseline characteristics of patients in Group A and Group B (Logistic regression analysis</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >变量</th><th align="center" valign="middle" >OR值(95%可信区间)</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >年龄(岁， x &#175; &#177; s )</td><td align="center" valign="middle" >1.061 (1.006~1.119)</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >年龄≥75岁(n，%)</td><td align="center" valign="middle" >1.435 (0.532~3.871)</td><td align="center" valign="middle" >0.476</td></tr><tr><td align="center" valign="middle" >心力衰竭</td><td align="center" valign="middle" >0.379 (0.197~0.729)</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >血管疾病</td><td align="center" valign="middle" >2.433 (0.972~6.090)</td><td align="center" valign="middle" >0.058</td></tr></tbody></table></table-wrap><p>表2. 两组患者多因素logistic回归分析</p></sec><sec id="s7_3"><title>3.3. CHADS2评分、CHA2DS2-VASc评分与颅内外大动脉粥样硬化的关系</title><p>根据脑血管影像学评估结果，将纳入研究的202例患者分为未合并颅内外大动脉粥样硬化狭窄组及合并颅内外大动脉粥样硬化狭窄组，两组间非参数检验结果显示，更高的CHA2DS2-VASc评分与房颤卒中合并颅内外大动脉粥样硬化狭窄相关(图1，P &lt; 0.05)，CHADS2评分在两组间未见明显差异(图2，P &gt; 0.05) (见表3)。</p><p>图1. CHA2DS2-VASc评分与颅内外大动脉粥样硬化</p><p>图2. CHADS2评分与颅内外大动脉粥样硬化</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Association between CHADS2 and CHA2DS2-VASC scores and LA</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >未合并颅内外大动脉粥样硬化狭窄</th><th align="center" valign="middle" >合并颅内外大动脉粥样硬化狭窄</th><th align="center" valign="middle" >Z值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >CHADS2评分(分)</td><td align="center" valign="middle" >4 (3~5)</td><td align="center" valign="middle" >4 (3~5)</td><td align="center" valign="middle" >−0.263</td><td align="center" valign="middle" >0.792</td></tr><tr><td align="center" valign="middle" >CHA2DS2-VASc评分(分)</td><td align="center" valign="middle" >5 (4~6)</td><td align="center" valign="middle" >6 (5~7)</td><td align="center" valign="middle" >−5.232</td><td align="center" valign="middle" >&lt;0.05</td></tr></tbody></table></table-wrap><p>表3. CHADS2评分、CHA2DS2-VASc评分与颅内外大动脉粥样硬化狭窄的关系</p></sec><sec id="s7_4"><title>3.4. CHADS2与CHA2DS2-VASc评分及评分项目预测颅内外大动脉粥样硬化狭窄的可行性</title><p>绘制ROC曲线，并应用AUC分析CHADS2、CHA2DS2-VASc评分预测颅内外LAS的可行性时，结果表明后者可以预测颅内外LAS [CHADS2评分AUC = 0.511 (0.425~0.597)，P &gt; 0.05；CHA2DS2-VASc评分AUC = 0.724 (0.650~0.797)，P &lt; 0.05] (图3)。两类评分的评分项目均对颅内外LAS有预测价值，但CHA2DS2-VASc评分项目[AUC = 0.731 (0.655~0.806)，P &lt; 0.001]的预测价值优于CHADS2评分项目[AUC = 0.705 (0.628~0.782)，P &lt; 0.001] (图4)。</p><p>图3. CHADS2与CHA2DS2-VASc评分预测颅内外LAS</p><p>图4. CHADS2与CHA2DS2-VASc评分项目预测颅内外LAS</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>急性缺血性卒中(AIS)在我国的发病率较高 [<xref ref-type="bibr" rid="hanspub.41715-ref10">10</xref>]，也是目前我国第一位致死病因。房颤是AIS的独立危险因素之一。经典TOSAT分型将房颤视为与大动脉粥样硬化相互独立的基础病因机制 [<xref ref-type="bibr" rid="hanspub.41715-ref13">13</xref>]。但临床常面临房颤卒中患者合并颅内外大动脉粥样硬化狭窄的情况，使病因分型更加复杂、困难。既往研究表明，CHADS2与冠状动脉疾病引起的左室壁节段活动迟缓、减弱存在相关性 [<xref ref-type="bibr" rid="hanspub.41715-ref14">14</xref>]，并且CHADS2和CHA2DS2-VASc评分均可以预测脑卒中患者的冠心病风险，CHADS2或CHA2DS2-VASc评分越高，冠心病的发生率越高，病情越严重 [<xref ref-type="bibr" rid="hanspub.41715-ref15">15</xref>]，提示以上两种评分也可能用于颅内外大动脉动脉粥样硬化程度的评估。但是多数房颤患者卒中风险的临床试验均未对纳入患者是否合并颅内外大动脉粥样硬化狭窄进行鉴别 [<xref ref-type="bibr" rid="hanspub.41715-ref16">16</xref>]，这使得如何精准区分AIS发生机制存在挑战。本研究纳入房颤卒中患者，旨在探讨CHADS2评分与CHA2DS2-VASc评分项目及评分预测房颤卒中合并颅内外大动脉粥样硬化狭窄的可能性，以及其他可能存在的相关预测因素。</p><p>CHADS2评分与CHA2DS2-VASc评分作为两种简单易行且效用较佳的预测工具，被用于心源性卒中再发风险的评估，并进一步指导抗栓方案的选择。“CHADS2评分”是5项评分内容的首字母缩写，即充血性心力衰竭(C)、高血压(H)、年龄 ≥ 75岁(A)、糖尿病(D)及既往缺血性卒中或短暂性脑缺血发作(S)，前四项均为每项1分，卒中病史为2分 [<xref ref-type="bibr" rid="hanspub.41715-ref17">17</xref>]。而CHA2DS2-VASc评分在CHA2DS2评分的基础上增加了血管疾病(V)、年龄65~74岁及女性(S) [<xref ref-type="bibr" rid="hanspub.41715-ref18">18</xref>]。随CHADS2评分与CHA2DS2-VASc评分增加，房颤患者发生栓塞事件的风险也会增加 [<xref ref-type="bibr" rid="hanspub.41715-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.41715-ref20">20</xref>]。但需要注意的是，两项评分中的评分项目在动脉粥样硬化的发生发展中也起到重要作用，如高血压既可以通过炎性与氧化应激加剧内皮损伤，也可以通过增加心脏负荷诱发房颤 [<xref ref-type="bibr" rid="hanspub.41715-ref21">21</xref>]；2型糖尿病患者的胰岛素缺乏可增加血小板粘度、加剧动脉粥样硬化血栓形成 [<xref ref-type="bibr" rid="hanspub.41715-ref22">22</xref>]，也可以通过高血糖状态损伤心肌细胞、使能量代谢紊乱，诱发房颤形成 [<xref ref-type="bibr" rid="hanspub.41715-ref23">23</xref>]。因此两项评分的评分项目也可能对预测AIS患者的大动脉粥样硬化狭窄有意义。本研究发现，针对两项评分的评分项目，未合并颅内外LAS与合并颅内外LAS的两组房颤卒中患者间，年龄、≥75岁、心力衰竭、血管疾病等对动脉粥样硬化狭窄的存在有提示作用，排除混杂因素后，年龄与心力衰竭表现出与颅内外LAS的独立相关性。提示在临床中，年龄更高、近期无心力衰竭的患者更可能合并颅内外大动脉LAS，在发病机制上，大动脉粥样硬化血栓形成机制需要得到更多的重视。</p><p>越来越多的研究已经证实，这两种评分系统也可用于各类心脑血管事件的预测。针对NVAF患者的全因死亡率研究表明，CHADS2和CHA2DS2-VASc评分不仅可以预测致命性缺血性卒中的发生，还可以预测致命性缺血性心脏病的发生 [<xref ref-type="bibr" rid="hanspub.41715-ref24">24</xref>]，CHADS2评分越高，患者的全因死亡率及心血管死亡率均较高 [<xref ref-type="bibr" rid="hanspub.41715-ref25">25</xref>]。鉴于动脉粥样硬化是一类全身性疾病，这为CHADS2和CHA2DS2-VASc评分预测评估颅内外大动脉粥样硬化的程度提供了可能。Kim YD [<xref ref-type="bibr" rid="hanspub.41715-ref3">3</xref>] 对780例持续性房颤患者进行动脉造影，结果显示发生动脉粥样硬化的颅内外大动脉数量与CHADS2评分呈现正相关。本研究显示，CHA2DS2-VASc评分较高与房颤卒中合并颅内外大动脉粥样硬化狭窄具有相关性，提示CHA2DS2-VASc评分也可用于房颤卒中的颅内外大动脉粥样硬化狭窄的评估与预测，但CHADS2评分则未显示出明确相关性。与CHADS2评分相比，CHA2DS2-VASc评分纳入的因素更多，能更准确地识别和区分房颤卒中的低、中风险患者，因此在识别合并动脉粥样硬化的房颤卒中时也可能更为灵敏。</p><p>当CHADS2和CHA2DS2-VASc评分大于等于2分时，指南建议口服抗凝药治疗以预防栓塞性事件地发生。然而针对更高评分层级的NVAF患者，目前仍不确定是否应制定不同的抗栓策略。尤其是对于房颤卒中患者，由于基础评分已为2分，当CHADS2和CHA2DS2-VASc评分高于2分时进一步区分层级似乎并无更多意义，虽然评分越高的患者预后相对更差 [<xref ref-type="bibr" rid="hanspub.41715-ref26">26</xref>]，但指南并未提供更多可靠的抗栓方案以供选择。并且尽管有足够的口服抗凝治疗，仍有部分患者反复出现脑血管事件 [<xref ref-type="bibr" rid="hanspub.41715-ref27">27</xref>] [<xref ref-type="bibr" rid="hanspub.41715-ref28">28</xref>]，这表明有其他机制参与了房颤卒中患者的再发卒中。虽然联合应用抗血小板药物与抗凝药物可能存在更高的出血风险 [<xref ref-type="bibr" rid="hanspub.41715-ref29">29</xref>]，但这种治疗和预防策略有必要被进一步评估以用于CHADS2和CHA2DS2-VASc评分更高的房颤卒中患者。本研究表明，CHADS2评分项目、CHA2DS2-VASc评分及评分项目可用于预测颅内外LAS的存在，CHA2DS2-VASc评分及评分项目效能更佳。这在一定程度上解释了为何CHADS2和CHA2DS2-VASc评分较高的患者有更高的再发卒中可能，提示仅凭CHA2DS2-VASc评分判断栓塞风险而忽视这些患者罹患大动脉粥样硬化型卒中的可能是不合理的。在房颤卒中患者中，更有必要行颅内外大动脉评估，突破以往经典TOAST分型标准做制定的分型细则，从而更加精准的选择抗凝治疗、抗血小板治疗或二者的联合治疗。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，本研究尝试探究了CHADS2和CHA2DS2-VASc评分及评分项目预测房颤卒中合并颅内外大动脉粥样硬化狭窄的可能性，对临床医师进一步区分房颤卒中的病因分型并选择抗栓方案有重要意义。</p></sec><sec id="s10"><title>文章引用</title><p>吴 昊,魏淑琦,赵仁亮. CHADS2与CHA2DS2-VASc评分预测房颤卒中患者颅内外大动脉粥样硬化狭窄Predicting Large Atherosclerotic Stenosis with CHADS2 and CHA2DS2-VASc Scores in Stroke Patients with Atrial Fibrillation[J]. 临床医学进展, 2021, 11(04): 1686-1694. https://doi.org/10.12677/ACM.2021.114242</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41715-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Writing Group M, Mozaffarian, D., Benjamin, E.J., et al. (2016) Heart Disease and Stroke Statistics—2016 Update: A Report from the American Heart Association. Circulation, 133, e38-e360.</mixed-citation></ref><ref id="hanspub.41715-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Adams, H.P., Bendixen, B.H., Kappelle, L.J., et al. (1993) Classification of Subtype of Acute Ischemic Stroke. Definitions for Use in a Multicenter Clinical Trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke, 24, 35-41.  
&lt;br&gt;https://doi.org/10.1161/01.STR.24.1.35</mixed-citation></ref><ref id="hanspub.41715-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Kim, Y.D., Cha, M.J., Kim, J., et al. (2011) Increases in Cerebral Atherosclerosis According to CHADS2 Scores in Patients with Stroke with Nonvalvular Atrial Fibrillation. Stroke, 42, 930-934.  
&lt;br&gt;https://doi.org/10.1161/STROKEAHA.110.602987</mixed-citation></ref><ref id="hanspub.41715-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Kim, S.J., Ryoo, S., Kwon, S., et al. (2013) Is Atrial Fibrillation Always a Culprit of Stroke in Patients with Atrial Fibrillation plus Stroke? Cerebrovascular Diseases, 36, 373-382. &lt;br&gt;https://doi.org/10.1159/000355571</mixed-citation></ref><ref id="hanspub.41715-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Cha, M.J., Kim, Y.D., Nam, H.S., Kim, J., Lee, D.H. and Heo, J.H. (2012) Stroke Mechanism in Patients with Non-Valvular Atrial Fibrillation According to the CHADS2 and CHA2 DS2-VASc Scores. European Journal of Neurology, 19, 473-479. &lt;br&gt;https://doi.org/10.1111/j.1468-1331.2011.03547.x</mixed-citation></ref><ref id="hanspub.41715-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会神经病学分会. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志, 2018, 51(59): 666-682.</mixed-citation></ref><ref id="hanspub.41715-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">中国高血压防治指南修订委员会, 中华医学会心血管病学分会, 等. 中国高血压防治指南2018[J]. 中国心血管杂志, 2019, 24(1): 24-56.</mixed-citation></ref><ref id="hanspub.41715-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版) [J]. 中国实用内科杂志, 2018, 38(4): 292-344.</mixed-citation></ref><ref id="hanspub.41715-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会中华心血管病杂志编辑委员会. 中国心力衰竭诊断与治疗指南2018[J] 中华心血管病杂志, 2018, 46(10): 760-789.</mixed-citation></ref><ref id="hanspub.41715-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Samuels, O.B., Joseph, G.J., Lynn, M.J., Smith, H.A. and Chimowitz, M.I. (2000) A Standardized Method for Measuring Intracranial Arterial Stenosis. American Journal of Neuroradiology, 21, 643-646.</mixed-citation></ref><ref id="hanspub.41715-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">(1991) North American Symptomatic Carotid Endarterectomy Trial. Methods, Patient Characteristics, and Progress. Stroke, 22, 711-720. &lt;br&gt;https://doi.org/10.1161/01.STR.22.6.711</mixed-citation></ref><ref id="hanspub.41715-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">January, C.T., Wann, L.S., Calkins, H., et al. (2019) 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Journal of the American College of Cardiology, 74, 104-132. &lt;br&gt;https://doi.org/10.1016/j.jacc.2019.01.011</mixed-citation></ref><ref id="hanspub.41715-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Goldstein, L.B., Bertels, C. and Davis, J.N. (1989) Interrater Reliability of the NIH Stroke Scale. Archives of Neurology, 46, 660-662. &lt;br&gt;https://doi.org/10.1001/archneur.1989.00520420080026</mixed-citation></ref><ref id="hanspub.41715-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Hoole, S.P., Heck, P.M., White, P.A., et al. (2010) Stunning and Cumulative Left Ventricular Dysfunction Occurs Late after Coronary Balloon Occlusion in Humans Insights from Simultaneous Coronary and Left Ventricular Hemodynamic Assessment. JACC: Cardiovascular Interventions, 3, 412-418. &lt;br&gt;https://doi.org/10.1016/j.jcin.2009.12.014</mixed-citation></ref><ref id="hanspub.41715-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Cha, M.J., Lee, H.S., Kim, Y.D., Nam, H.S. and Heo, J.H. (2013) The Association between Asymptomatic Coronary Artery Disease and CHADS2 and CHA2 DS2-VASc Scores in Patients with Stroke. European Journal of Neurology, 20, 1256-1263. &lt;br&gt;https://doi.org/10.1111/ene.12158</mixed-citation></ref><ref id="hanspub.41715-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Granger, C.B., Alexander, J.H., McMurray, J.J., et al. (2011) Apixaban versus Warfarin in Patients with Atrial Fibrillation. The New England Journal of Medicine, 365, 981-992. &lt;br&gt;https://doi.org/10.1056/NEJMoa1107039</mixed-citation></ref><ref id="hanspub.41715-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Gage, B.F., Waterman, A.D., Shannon, W., Boechler, M., Rich, M.W. and Radford, M.J. (2001) Validation of Clinical Classification Schemes for Predicting Stroke: Results from the National Registry of Atrial Fibrillation. JAMA, 285, 2864-2870. &lt;br&gt;https://doi.org/10.1001/jama.285.22.2864</mixed-citation></ref><ref id="hanspub.41715-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Lip, G.Y., Frison, L., Halperin, J.L. and Lane, D.A. (2010) Identifying Patients at High Risk for Stroke Despite Anticoagulation: A Comparison of Contemporary Stroke Risk Stratification Schemes in an Anticoagulated Atrial Fibrillation Cohort. Stroke, 41, 2731-2738. &lt;br&gt;https://doi.org/10.1161/STROKEAHA.110.590257</mixed-citation></ref><ref id="hanspub.41715-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Puwanant, S., Varr, B.C., Shrestha, K., et al. (2009) Role of the CHADS2 Score in the Evaluation of Thromboembolic Risk in Patients with Atrial Fibrillation Undergoing Transesophageal Echocardiography before Pulmonary Vein Isolation. Journal of the American College of Cardiology, 54, 2032-2039. &lt;br&gt;https://doi.org/10.1016/j.jacc.2009.07.037</mixed-citation></ref><ref id="hanspub.41715-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Rietbrock, S., Heeley, E., Plumb, J. and van Staa, T. (2008) Chronic Atrial Fibrillation: Incidence, Prevalence, and Prediction of Stroke Using the Congestive Heart Failure, Hypertension, Age &gt;75, Diabetes Mellitus, and Prior Stroke or Transient Ischemic Attack (CHADS2) Risk Stratification Scheme. American Heart Journal, 156, 57-64.  
&lt;br&gt;https://doi.org/10.1016/j.ahj.2008.03.010</mixed-citation></ref><ref id="hanspub.41715-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Gallagher, R., Zhang, L., Roach, K., et al. (2015) Profile of Atrial Fibrillation Inpatients: Cardiovascular Risk Factors and Cardiac Rehabilitation Programme Delivery and Referral Patterns. International Journal of Nursing Practice, 21, 749-755. &lt;br&gt;https://doi.org/10.1111/ijn.12337</mixed-citation></ref><ref id="hanspub.41715-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Baalbaki, H.A. and Bell, D.S. (2007) Insulin Resistance and Thrombogenesis: Recent Insights and Therapeutic Implications. Endocrine Practice: Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 13, 679-686. &lt;br&gt;https://doi.org/10.4158/EP.13.6.679</mixed-citation></ref><ref id="hanspub.41715-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Saito, S., Teshima, Y., Fukui, A., et al. (2014) Glucose Fluctuations Increase the Incidence of Atrial Fibrillation in Diabetic Rats. Cardiovascular Research, 104, 5-14. &lt;br&gt;https://doi.org/10.1093/cvr/cvu176</mixed-citation></ref><ref id="hanspub.41715-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Henriksson, K.M., Farahmand, B., Johansson, S., Asberg, S., Terent, A. and Edvardsson, N. (2010) Survival after Stroke—The Impact of CHADS2 Score and Atrial Fibrillation. International Journal of Cardiology, 141, 18-23.  
&lt;br&gt;https://doi.org/10.1016/j.ijcard.2008.11.122</mixed-citation></ref><ref id="hanspub.41715-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Goto, S., Bhatt, D.L., Rother, J., et al. (2008) Prevalence, Clinical Profile, and Cardiovascular Outcomes of Atrial Fibrillation Patients with Atherothrombosis. American Heart Journal, 156, 855-863.  
&lt;br&gt;https://doi.org/10.1016/j.ahj.2008.06.029</mixed-citation></ref><ref id="hanspub.41715-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Kim, Y.D., Park, B., Cha, M.J., et al. (2010) Stroke Severity in Concomitant Cardiac Sources of Embolism in Patients with Atrial Fibrillation. Journal of the Neurological Sciences, 298, 23-27. &lt;br&gt;https://doi.org/10.1016/j.jns.2010.08.011</mixed-citation></ref><ref id="hanspub.41715-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Hart, R.G., Pearce, L.A., Miller, V.T., et al. (2000) Cardioembolic vs. Noncardioembolic Strokes in Atrial Fibrillation: Frequency and Effect of Antithrombotic Agents in the Stroke Prevention in Atrial Fibrillation Studies. Cerebrovascular Diseases, 10, 39-43. &lt;br&gt;https://doi.org/10.1159/000016023</mixed-citation></ref><ref id="hanspub.41715-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Evans, A., Perez, I., Yu, G. and Kalra, L. (2001) Should Stroke Subtype Influence Anticoagulation Decisions to Prevent Recurrence in Stroke Patients with Atrial Fibrillation? Stroke, 32, 2828-2832.  
&lt;br&gt;https://doi.org/10.1161/hs1201.099520</mixed-citation></ref><ref id="hanspub.41715-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Hankey, G.J. and Eikelboom, J.W. (2010) Antithrombotic Drugs for Patients with Ischaemic Stroke and Transient Ischaemic Attack to Prevent Recurrent Major Vascular Events. The Lancet Neurology, 9, 273-284.  
&lt;br&gt;https://doi.org/10.1016/S1474-4422(10)70038-7</mixed-citation></ref></ref-list></back></article>